Australia - engelsk - APVMA (Australian Pesticides and Veterinary Medicines Authority)

basf australia ltd - guazatine - fungicide - citrus - post-harvest dip | rockmelon or canteloup - post-harvest | canteloup | musk melon - alternaria leaf blight or spot blight | blue mould on citrus - p. italicum | cladosporium on rockmelon | fusarium fruit rot | green mould | mucor soft rot | sour or yeasty rot | stem end rots | alternaria leaf spot | alternata spot | brown spot | leaf spot - alternaria spp.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - phentermine hydrochloride, quantity: 49.79 mg (equivalent: phentermine, qty 40 mg) - capsule, modified release - excipient ingredients: lactose monohydrate; sodium polystyrene sulfonate; magnesium stearate; liquid paraffin; titanium dioxide; purified water; sunset yellow fcf; erythrosine; gelatin; iron oxide black; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; ethanol; shellac; sulfuric acid - phentermine sandoz is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater. the treatment with phentermine sandoz can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2), which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - phentermine hydrochloride, quantity: 18.67 mg (equivalent: phentermine, qty 15 mg) - capsule, modified release - excipient ingredients: lactose monohydrate; sodium polystyrene sulfonate; magnesium stearate; liquid paraffin; titanium dioxide; brilliant blue fcf; sunset yellow fcf; purified water; quinoline yellow; gelatin; iron oxide black; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; ethanol; shellac; sulfuric acid - phentermine sandoz is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater. the treatment with phentermine sandoz can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2), which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - phentermine hydrochloride, quantity: 37.34 mg (equivalent: phentermine, qty 30 mg) - capsule, modified release - excipient ingredients: lactose monohydrate; sodium polystyrene sulfonate; magnesium stearate; liquid paraffin; titanium dioxide; purified water; iron oxide red; gelatin; iron oxide black; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; ethanol; shellac; sulfuric acid - phentermine sandoz is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater. the treatment with phentermine sandoz can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2), which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - allopurinol, quantity: 100 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; magnesium stearate; povidone; macrogol 8000; purified talc; sodium lauryl sulfate - indications as at 11 may 2001: main clinical manifestations of urate/uric acid deposition. these are gouty arthritis, skin tophi and/or renal involvement through crystal deposition or stone formation. such clinical manifestations may occur in idiopathic gout, uric acid lithiasis, acute uric acid nephropathy, neoplastic disease and myeloproliferative disease with high cell turnover rates, in which high urate levels occur either spontaneously or after cytotoxic therapy, certain enzyme disorders which lead to overproduction of urate and involve hypoxanthine guanine phosphoribosyltransferase including lesch-nyhan syndrome, glucose-6-phosphatase including glycogen storage disease, phosphoribosylpyrophosphate synthetase, phosphoribosylpyrophosphate amidotransferase. progout is indicated for the management of 2,8-dihydroxyadenine (2,8-dha) renal stones related to deficient activity of adenine phosphoribosyltransferase. progout is indicated for the management of recurrent mixed calcium oxalate renal stones in the p

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - allopurinol, quantity: 300 mg - tablet - excipient ingredients: maize starch; magnesium stearate; povidone; sodium starch glycollate; maltodextrin; microcrystalline cellulose - indications as at 11 may 2001: main clinical manifestations of urate/uric acid deposition. these are gouty arthritis, skin tophi and/or renal involvement through crystal deposition or stone formation. such clinical manifestations may occur in idiopathic gout, uric acid lithiasis, acute uric acid nephropathy, neoplastic disease and myeloproliferative disease with high cell turnover rates, in which high urate levels occur either spontaneously or after cytotoxic therapy, certain enzyme disorders which lead to overproduction of urate and involve hypoxanthine guanine phosphoribosyltransferase including lesch-nyhan syndrome, glucose-6-phosphatase including glycogen storage disease, phosphoribosylpyrophosphate synthetase, phosphoribosylpyrophosphate amidotransferase. progout is indicated for the management of 2,8-dihydroxyadenine (2,8-dha) renal stones related to deficient activity of adenine phosphoribosyltransferase. progout is indicated for the management of recurrent mixed calcium oxalate renal stones in the p

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - allopurinol, quantity: 300 mg - tablet, uncoated - excipient ingredients: povidone; lactose monohydrate; maize starch; sodium starch glycollate; stearic acid - indications as at 6 february 2003: main clinical manifestations of urate/uric acid deposition. these are gouty arthritis, skin tophi and/or renal involvement through crystal deposition or stone formation. such clinical manifestations may occur in: idiopathic gout; uric acid lithiasis; acute uric acid nephropathy; neoplastic disease and myeloproliferative disease with high cell turnover rates, in which high urate levels occur either spontaneously or after cytotoxic therapy, certain enzyme disorders which lead to overproduction of urate and involve: hypoxanthine guanine phosphoriboslytransferase including lesch-nyhan syndrome, glucose 6-phosphatase including glycogen storage disease, phosphoribosylpyrophosphate synthetase, phosphoribosylpyrophosphate amidotransferase. allopurinol-arx is indicated for the management of 2,8-dihydroxyadenine (2,8-dha) renal stones related to deficient activity of adenine phosphoribosyl transferase. allopurinol-arx is indicated for the management of recurred mixed calcium oxalate r

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - allopurinol, quantity: 100 mg - tablet, uncoated - excipient ingredients: povidone; maize starch; lactose monohydrate; stearic acid - indications as at 6 february 2003: main clinical manifestations of urate/uric acid deposition. these are gouty arthritis, skin tophi and/or renal involvement through crystal deposition or stone formation. such clinical manifestations may occur in: idiopathic gout; uric acid lithiasis; acute uric acid nephropathy; neoplastic disease and myeloproliferative disease with high cell turnover rates, in which high urate levels occur either spontaneously or after cytotoxic therapy, certain enzyme disorders which lead to overproduction of urate and involve: hypoxanthine guanine phosphoriboslytransferase including lesch-nyhan syndrome, glucose 6-phosphatase including glycogen storage disease, phosphoribosylpyrophosphate synthetase, phosphoribosylpyrophosphate amidotransferase. allopurinol-arx is indicated for the management of 2,8-dihydroxyadenine (2,8-dha) renal stones related to deficient activity of adenine phosphoribosyl transferase. allopurinol-arx is indicated for the management of recurred mixed calcium oxalate renal stones in the presence of hyperuricosuria, when fluid, dietary and similar measures have failed.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - allopurinol, quantity: 300 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; povidone; sodium starch glycollate; stearic acid - indications as at 6 february 2003: main clinical manifestations of urate/uric acid deposition. these are gouty arthritis, skin tophi and/or renal involvement through crystal deposition or stone formation. such clinical manifestations may occur in: idiopathic gout; uric acid lithiasis; acute uric acid nephropathy; neoplastic disease and myeloproliferative disease with high cell turnover rates, in which high urate levels occur either spontaneously or after cytotoxic therapy, certain enzyme disorders which lead to overproduction of urate and involve: hypoxanthine guanine phosphoriboslytransferase including lesch-nyhan syndrome, glucose 6-phosphatase including glycogen storage disease, phosphoribosylpyrophosphate synthetase, phosphoribosylpyrophosphate amidotransferase. allopurinol-str is indicated for the management of 2,8-dihydroxyadenine (2,8-dha) renal stones related to deficient activity of adenine phosphoribosyl transferase. allopurinol-str is indicated for the management of recurred mixed calcium oxalate renal stones in the presence of hyperuricosuria, when fluid, dietary and similar measures have failed.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - allopurinol, quantity: 100 mg - tablet, uncoated - excipient ingredients: maize starch; lactose monohydrate; povidone; stearic acid - indications as at 6 february 2003: main clinical manifestations of urate/uric acid deposition. these are gouty arthritis, skin tophi and/or renal involvement through crystal deposition or stone formation. such clinical manifestations may occur in: idiopathic gout; uric acid lithiasis; acute uric acid nephropathy; neoplastic disease and myeloproliferative disease with high cell turnover rates, in which high urate levels occur either spontaneously or after cytotoxic therapy, certain enzyme disorders which lead to overproduction of urate and involve: hypoxanthine guanine phosphoriboslytransferase including lesch-nyhan syndrome, glucose 6-phosphatase including glycogen storage disease, phosphoribosylpyrophosphate synthetase, phosphoribosylpyrophosphate amidotransferase. allopurinol-str is indicated for the management of 2,8-dihydroxyadenine (2,8-dha) renal stones related to deficient activity of adenine phosphoribosyl transferase. allopurinol-str is indicated for the management of recurred mixed calcium oxalate renal stones in the presence of hyperuricosuria, when fluid, dietary and similar measures have failed.